ITM to Highlight Innovations in Neuroendocrine Tumor Treatment

Advancements in Neuroendocrine Tumor Treatment by ITM

ITM Isotope Technologies Munich SE (ITM), a frontrunner in the radiopharmaceutical industry, is set to unveil significant insights from the post hoc subgroup analyses of its recent Phase 3 COMPETE trial. This event will take place during the prestigious North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium scheduled from October 22 to October 25. The symposium will convene in Austin to unite experts in the field of neuroendocrine tumors, focusing on innovative treatment approaches.

Details of the Oral Presentation

During the symposium, a pivotal oral presentation will be delivered, showcasing the efficacy of ¹⁷⁷Lu-edotreotide compared to everolimus in patients diagnosed with Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This presentation, titled Efficacy of ¹⁷⁷Lu-edotreotide vs Everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses), is scheduled for Friday, October 24, from 3:35 pm to 4:50 pm CDT. The session will be featured among noted abstracts addressing advancements in targeted therapies and molecular imaging.

Information About the Presenter

The presentation will be conducted by Dr. Jaume Capdevila, a distinguished investigator and senior medical oncologist at Vall d'Hebron University Hospital in Barcelona. His presentation will convey crucial findings that emphasize the effectiveness of targeted therapies in managing neuroendocrine tumors.

Satellite Symposium on Novel Therapeutic Strategies

In addition to the oral presentation, ITM will also facilitate a satellite symposium titled What’s Your Next Move? Sequencing Therapies in GEP-NETs. Scheduled for the same day, from 7:00 am to 8:00 am CDT, this symposium will be moderated by Dr. Namrata Vijayvergia, a respected figure in gastrointestinal medical oncology. She will be joined by a panel of experts, including Dr. Jessica Maxwell, Dr. Jonathan Strosberg, and Dr. Harshad Kulkarni, who will discuss innovative strategies for sequencing therapies in neuroendocrine cancer care.

Insights from the COMPETE Trial

The COMPETE trial (NCT03049189) has made significant strides in the evaluation of ¹⁷⁷Lu-edotreotide (ITM-11) as a proprietary, synthetic targeted radiotherapeutic agent. This investigational treatment demonstrated a remarkable improvement in progression-free survival when compared with everolimus among patients with inoperable and progressive GEP-NETs. Such findings are instrumental in establishing more effective treatment protocols for this challenging subset of patients.

About ITM Isotope Technologies Munich SE

As a leader in the radiopharmaceutical sector, ITM is committed to pioneering new generations of therapeutics and diagnostics targeted at complex tumors. Their mission includes fulfilling the expectations of patients and medical professionals by excelling in the development, production, and global supply of medical isotopes. ITM aims to enhance patient outcomes through their advanced precision oncology pipeline, which includes numerous ongoing Phase 3 studies that combine high-quality radioisotopes with various targeting molecules.

With over two decades of experience in radiopharmaceutical research and development, ITM is strategically positioned to make significant contributions to cancer treatment. Their continuous efforts focus on delivering targeted therapies that aim to maximize clinical benefits and improve the patients' quality of life.

Contact Information for ITM

For further inquiries, ITM encourages interested parties to reach out through their corporate communications team or investor relations:

Corporate Communications

Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com

Investor Relations

Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com

Frequently Asked Questions

What will ITM present at the NANETS symposium?

ITM will present data from the post hoc analyses of its Phase 3 COMPETE trial, highlighting the effectiveness of ¹⁷⁷Lu-edotreotide in treating GEP-NETs.

Who is the presenter of the Phase 3 COMPETE trial findings?

Dr. Jaume Capdevila, a senior medical oncologist, will present the findings at the symposium.

When and where will the satellite symposium occur?

The satellite symposium titled What’s Your Next Move? will occur on October 24, from 7:00 am - 8:00 am CDT at the JW Marriott Austin.

What are GEP-NETs?

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that can develop in the gastrointestinal tract and pancreas, and treatment options are limited.

How can I contact ITM for more information?

You can contact ITM's corporate communications team or investor relations through the provided email addresses or phone numbers.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.